Newron and EA Pharma (a subsidiary of Eisai Co., Ltd.) announce license agreement for Evenamide in Japan and other Asian territories
Ad hoc announcement pursuant to Art. 53 LR Newron will receive up to a maximum of €117 million from an upfront payment, development milestones and commercialization milestones, and up to double-digit tiered royalties on net sales Evenamide is a unique modulator of